Effect of dapson in treatment of pemphigus vulgaris

Phase 2

• Conditions: Pemphigus vulgaris.; Pemphigus vulgaris

• Registration Number: IRCT201307133566N2
• Lead Sponsor: Tabriz university of medical sciences, assistance research

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Inclusion criterion: patients with pemphigus vulgaris, that their disease was detected by the clinical or pathological evidence of initial tests with pemphigus vulgaris. Exclusion criterion: patients who were G6PDD.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severity of damage. Timepoint: The patients for eleven months and at weeks zero, one, two, three, and four, two months later, three months later, fiv months later e, seven months later, nine months later and eleven months later of treatment follow up. Method of measurement: Physical examination.

Secondary Outcome Measures

Name	Time	Method
ipid profile. Timepoint: The patients for eleven months and at weeks zero, one, two, three, and four, two months later, three months later, fiv months later e, seven months later, nine months later and eleven months later of treatment follow up. Method of measurement: Lab tests.;HTN. Timepoint: the patients for eleven months and at weeks zero, one, two, three, and four, two months later, three months later, fiv months later e, seven months later, nine months later and eleven months later of treatment follow up. Method of measurement: lab.;Liver function test. Timepoint: The patients for eleven months and at weeks zero, one, two, three, and four, two months later, three months later, fiv months later e, seven months later, nine months later and eleven months later of treatment follow up. Method of measurement: Lab tests.